國立虎尾科技大學 |

Neuroeconomic Markers of Opioid Use Disorder Outcomes : = A Computational Psychiatry Approach.

紀錄類型:	書目-語言資料,手稿 : Monograph/item
正題名/作者:	Neuroeconomic Markers of Opioid Use Disorder Outcomes :/
其他題名:	A Computational Psychiatry Approach.
作者:	Lopez-Guzman, Silvia.
面頁冊數:	1 online resource (196 pages)
附註:	Source: Dissertation Abstracts International, Volume: 79-08(E), Section: B.
Contained By:	Dissertation Abstracts International79-08B(E).
標題:	Neurosciences. -
電子資源:	click for full text (PQDT)
ISBN:	9780355773743

Neuroeconomic Markers of Opioid Use Disorder Outcomes : = A Computational Psychiatry Approach.
Lopez-Guzman, Silvia.

Neuroeconomic Markers of Opioid Use Disorder Outcomes :A Computational Psychiatry Approach. - 1 online resource (196 pages)

Source: Dissertation Abstracts International, Volume: 79-08(E), Section: B.

Thesis (Ph.D.)--New York University, 2018.

Includes bibliographical references

The exponential increase in opioid addiction cases in the country has resulted in hundreds of thousands of individuals seeking treatment services. Medication Assisted Treatment (MAT)---a combination of an opioid substitute and psychosocial intervention---is the gold standard for opioid use disorder. It improves clinical outcomes, reducing the risk of overdose and of infectious comorbidities. However, two major issues challenge its effectiveness. First, access and availability to MAT facilities is limited, and second, MAT is hindered by very high rates of relapse and dropout. Patients often dangerously combine their opioid maintenance medication with illicit opioids like heroin or fentanyl, risking an overdose.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2018

Mode of access: World Wide Web

ISBN: 9780355773743Subjects--Topical Terms:

593561
Neurosciences.
Index Terms--Genre/Form:

554714
Electronic books.

Neuroeconomic Markers of Opioid Use Disorder Outcomes : = A Computational Psychiatry Approach.
LDR:05561ntm a2200409Ki 4500 001 916620
005 20180927111920.5
006 m o u
007 cr mn||||a|a||
008 190606s2018 xx obm 000 0 eng d
020 $a 9780355773743
035 $a (MiAaPQ)AAI10682960
035 $a (MiAaPQ)nyu:13145
035 $a AAI10682960
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Lopez-Guzman, Silvia. $3 1190415
245 1 0 $a Neuroeconomic Markers of Opioid Use Disorder Outcomes : $b A Computational Psychiatry Approach.
264 0 $c 2018
300 $a 1 online resource (196 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertation Abstracts International, Volume: 79-08(E), Section: B.
500 $a Adviser: Paul W. Glimcher.
502 $a Thesis (Ph.D.)--New York University, 2018.
504 $a Includes bibliographical references
520 $a The exponential increase in opioid addiction cases in the country has resulted in hundreds of thousands of individuals seeking treatment services. Medication Assisted Treatment (MAT)---a combination of an opioid substitute and psychosocial intervention---is the gold standard for opioid use disorder. It improves clinical outcomes, reducing the risk of overdose and of infectious comorbidities. However, two major issues challenge its effectiveness. First, access and availability to MAT facilities is limited, and second, MAT is hindered by very high rates of relapse and dropout. Patients often dangerously combine their opioid maintenance medication with illicit opioids like heroin or fentanyl, risking an overdose.
520 $a To tackle these problems, we need to understand the mechanisms behind relapse and develop tools that can aid in the personalized prediction and prevention of these events. Neuroscience has made great progress over the past 40 years in the understanding of the circuitry and neuromodulatory mechanisms involved in addiction and relapse. However, these insights have not yet translated into the clinical tools we need. One way to bridge addiction neurobiology and clinical reality is to utilize computational models of behavior that 1) serve to objectively parametrize the decision processes that could be leading to drug taking during treatment, and 2) have been shown to engage the very neural substrates that are relevant to relapse and to the vicious cycle of addiction.
520 $a In this dissertation, my collaborators and I propose to deploy this computational psychiatry approach to focus on two decision-making dimensions that are directly relevant to the problem of engaging in drug taking while seeking abstinence: impulsive (impatient) decision-making, and risky decision-making. Several previous studies have laid the groundwork for this, suggesting these processes are relevant to opioid use disorder, may reflect both stable personality traits and context-dependent effects, and are potentially affected by treatment.
520 $a We followed a cohort of patients with opioid use disorder in a MAT clinic for the first seven months of their treatment, and a cohort of matched controls. Along this follow-up period, we assessed repeatedly their intertemporal choice and risk-uncertainty preferences, and derived 3 individualized computational parameters from validated neuroeconomic models---discount rate, risk tolerance, and ambiguity tolerance---as putative measures of impulsive choice, attitudes to known risks, and attitudes to unknown risks. Simultaneously, we assessed craving, withdrawal, and anxiety levels in our patient cohort, establishing the relationship between the behavioral decision-making parameters and the symptomatology. Most importantly, we evaluated the parameters' contribution to individual clinical outcomes, such as concomitant illicit drug use and full relapse.
520 $a Our results indicate that standard models of intertemporal choice result in systematically biased discount rates, due to an often-ignored distortion effect caused by risk preferences. This can lead to wrong interpretations about differences in impulsivity across groups of individuals and conditions. Our new proposed modeling approach allowed us to disassociate these parameters so that they reflect separable decision-making processes.
520 $a Using this methodology, we found that relative increases in impulsive decision-making and in tolerance of unknown risks were proximally predictive of concomitant opioid use. We also found a correlation between fluctuations in craving and fluctuations in discounting. Having established this behaviorally, we explored the connection between illicit opioid use in these patients and the neural mechanisms behind impulsive decision-making. We identified a link between craving and the neural correlates of intertemporal choice that could point to the computational mechanism behind craving and relapse. Taken together, our results show a distinguishable role for these specific value computations in relating to treatment outcomes for opioid use disorder. We found that they have good clinical validity, and may be useful in the design of computational predictive tools for relapse.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2018
538 $a Mode of access: World Wide Web
650 4 $a Neurosciences. $3 593561
650 4 $a Cognitive psychology. $3 556029
650 4 $a Medicine. $3 644133
655 7 $a Electronic books. $2 local $3 554714
690 $a 0317
690 $a 0633
690 $a 0564
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a New York University. $b Neural Science. $3 1190416
773 0 $t Dissertation Abstracts International $g 79-08B(E).
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10682960 $z click for full text (PQDT)